.Attribute Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view requires incorporation of individuals along with MASLD and size of liver results in cardio-- renal-- metabolic trials, when records propose mechanistically conceivable benefits and scientific safety and security-- and also describes factors for trial layout as well as regulatory commendation.